Non-Alcoholic Fatty Liver (NAFL)

This six-month human clinical trial showed that Basis, at the recommended dose, reduced several markers of liver inflammation in healthy adults with fatty liver. The results, published in Hepatology, also further confirmed that Basis is safe and well tolerated and supports liver function in healthy individuals. Publication here. Identifier: NCT03513523

Related Articles: